Hemoglobinuria, Paroxysmal
"Hemoglobinuria, Paroxysmal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition characterized by the recurrence of HEMOGLOBINURIA caused by intravascular HEMOLYSIS. In cases occurring upon cold exposure (paroxysmal cold hemoglobinuria), usually after infections, there is a circulating antibody which is also a cold hemolysin. In cases occurring during or after sleep (paroxysmal nocturnal hemoglobinuria), the clonal hematopoietic stem cells exhibit a global deficiency of cell membrane proteins.
MeSH Number(s)
C15.378.071.141.560
C15.378.190.625.460
Concept/Terms
Paroxysmal Cold Hemoglobinuria- Paroxysmal Cold Hemoglobinuria
- Hemoglobinuria, Paroxysmal Cold
- Paroxysmal Hemoglobinuria, Cold
- Cold Paroxysmal Hemoglobinuria
- Hemoglobinuria, Cold Paroxysmal
Paroxysmal Nocturnal Hemoglobinuria- Paroxysmal Nocturnal Hemoglobinuria
- Hemoglobinuria, Paroxysmal Nocturnal
- Marchiafava-Micheli Syndrome
- Marchiafava Micheli Syndrome
- Syndrome, Marchiafava-Micheli
- Paroxysmal Hemoglobinuria, Nocturnal
- Hemoglobinuria, Nocturnal Paroxysmal
- Nocturnal Paroxysmal Hemoglobinuria
Below are MeSH descriptors whose meaning is more general than "Hemoglobinuria, Paroxysmal".
Below are MeSH descriptors whose meaning is more specific than "Hemoglobinuria, Paroxysmal".
This graph shows the total number of publications written about "Hemoglobinuria, Paroxysmal" by people in Harvard Catalyst Profiles by year, and whether "Hemoglobinuria, Paroxysmal" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 5 | 1 | 6 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 4 | 0 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 4 | 0 | 4 |
| 2018 | 4 | 0 | 4 |
| 2019 | 2 | 0 | 2 |
| 2021 | 4 | 0 | 4 |
| 2022 | 1 | 0 | 1 |
| 2023 | 6 | 0 | 6 |
| 2024 | 1 | 0 | 1 |
Below are the most recent publications written about "Hemoglobinuria, Paroxysmal" by people in Profiles.
-
Treatment Patterns and Healthcare Resource Utilization of Patients With Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Claims Data Analysis. Clin Appl Thromb Hemost. 2024 Jan-Dec; 30:10760296231213073.
-
Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants? Hematology Am Soc Hematol Educ Program. 2023 Dec 08; 2023(1):135-140.
-
Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape. Blood Rev. 2024 Mar; 64:101158.
-
Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis. Adv Ther. 2024 Jan; 41(1):413-430.
-
Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients. Orphanet J Rare Dis. 2023 Jun 30; 18(1):172.
-
Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison. Adv Ther. 2023 04; 40(4):1571-1589.
-
Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition. Blood Rev. 2023 05; 59:101041.
-
Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria. Adv Ther. 2022 05; 39(5):1959-1975.
-
Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Curr Med Res Opin. 2021 11; 37(11):1913-1923.
-
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. Adv Ther. 2021 08; 38(8):4461-4479.